Nonmyeloablative allogeneic stem cell transplantation in metastatic renal cell carcinoma: A new therapeutic option or just a clinical experiment?

World Journal of Urology

Volumn 23, Issue 3, 2005, Pages 213-220

  Roigas, Jan ^a   Massenkeil, Gero ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Donor lymphocyte infusions; Graft versus tumor effect; Metastatic renal cell carcinoma; Nonmyeloablative stem cell transplantation

Indexed keywords

ADOPTIVE TRANSFER; ALLOTRANSPLANTATION; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; METHODOLOGY; REVIEW; STEM CELL TRANSPLANTATION;

ADOPTIVE TRANSFER; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 23744480522     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-004-0480-2     Document Type: Review

References (51)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M (2003) Cancer Statistics, 2003. CA Cancer J Clin 53:5-26 12568441
2. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland (2004) Krebs in Deutschland. 4. Überarbeitete, aktualisierte Ausgabe. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland, Saarbrücken, (http://www.rki.de/KREBS)
3. Mickisch GHJ, Garin A, Van Pappel H, De Prijck L, Sylvester R, and members of the European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group (2001) Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon-alpha alone in metastatic renal-cell-carcinoma: A randomised trial. Lancet 358:966-970 10.1016/S0140-6736(01)06103-7
4. Levy DA, Slaton JW, Swanson DA, Dinney CP (1998) Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159:1163-1167 10.1097/00005392-199804000-00014
5. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492 1:STN:280:BimD2c%2Fjt1w%3D
6. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JRJr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655-1659 10.1056/NEJMoa003013
7. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M (2004) Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188-1194 10.1200/JCO.2004.06.155
8. Roigas J, Deger S, Taymoorian K, Wille AH, Johannsen M, Turk I, Schnorr D, Loening SA (2003) Effects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma - results of a retrospective analysis. Cancer Biother Radiopharm 18:157-163 10.1089/108497803765036328
9. Coppin C, Porzsolt F, Kumpf J, Coldmann A, Wilt T (2000) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 3:1-27 (CD001425)
10. Negrier S, Caty A, Lesimple T, Douillard J-Y, Escudier B, Rossi J-F, Viens P, Gomez F (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 18:4009-4015 1:CAS:528:DC%2BD3MXktFegtg%3D%3D
11. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750-758 10.1056/NEJM200009143431101
12. Jacobson LO, Simmons EL, Marks EK, Eldredge JH (1951) Recovery from radiation injury. Science 113:510-511
13. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300:1068-1073 1:STN:280:CSaC2MnmvVQ%3D
14. Apperley JF, Jones L, Hale G, Waldmann H, Hows J, Rombos Y, Tsatalas C, Marcus RE, Goolden AW, Gordon-Smith EC (1986) Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1:53-66
15. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562 1:STN:280:By%2BC38zhs1w%3D
16. Ringden O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, Harrousseau JL, Fiere D, Bacigalupo A, Frassoni F, Gorin NC (1996) Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 18:921-929
17. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, Van Rhee F, Mittermueller J, De Witte T, Holler E, Ansari H for the European Group for Blood and Marrow Transplantation Working Party Chronic Leucemia (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050 1:CAS:528:DyaK2MXnslKqs74%3D
18. Goulmy E (2004) Minor histocompatibility antigens: Allo target molecules for tumor-specific immunotherapy. Cancer J 10:1-7
19. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL (1997) Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood 90:3204-3213
20. Beelen DW, Haralambie E, Brandt H, Linzenmeier G, Muller KD, Quabeck K, Sayer HG, Graeven U, Mahmoud HK, Schaefer UW (1992) Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 80:2668-2676
21. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, Read EJ, Carter C, Bahceci E, Young NS, Barrett AJ (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 94:3234-3241 1:CAS:528:DyaK1MXntVSrtLs%3D
22. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531-4536 1:CAS:528:DyaK2sXjvFCkt7g%3D
23. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematological diseases. Blood 91:756-763 1:STN:280:DyaK1c7hvVWrtQ%3D%3D
24. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400 10.1182/blood.V97.11.3390
25. Mapara MY, Kim Y-M, Wang SP, Bronson R, Sachs DH, Sykes M (2002) Donor lymphocyte infusions (DLI) mediate superior graft-versus-leukemia (GvL) effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen-presenting cells. Blood 100:1903-1909 10.1182/ blood-2002-01-0023
26. Parker JE, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M, Prentice G, Garg M, Yin JA, Byrne J, Russell NH, Mufti GJ (2002) Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 119:144-154 10.1046/j.1365-2141.2002.03796.x
27. Dreger P, Van Biezen A, Brand R, Esteve J, Martino R, Deliliers GL, Hansz J, Fine J, Kimby E, Milligan D, Michallet M, Niederwieser DW (2003) Reduced-intensity conditioning lowers treatment-related mortality (TRM) of allogeneic stem cell transplantation (SCT) for CLL: A retrospective study on 448 patients. Blood 102:197a
28. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG, Sandmaier BM, Storb R (2004) Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104:1550-1558 10.1182/blood-2004-03-0804
29. Morecki S, Yacovlev E, Gelfand Y, Uzi I, Slavin S (2001) Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma. J Immunother 24:114-121 10.1097/00002371-200103000-00005
30. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, Bock G, Gassner C, Schiller L, Petersen F, Niederwieser D (1996) Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501-1508 1:CAS:528:DyaK28XkvF2jsbs%3D
31. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Korbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, Van Besien K, Hortobagyi GN, Champlin RE (1998) Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16:986-993 1:STN:280:DyaK1c7mslKjtA%3D%3D
32. Bay JO, Fleury J, Choufi B, Tournilhac O, Vincent C, Bailly C, Dauplat J, Viens P, Faucher C, Blaise D (2002) Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: Results of five patients. Bone Marrow Transplant 30:95-102 10.1038/sj.bmt.1703609
33. Figlin RA, Pierce WC, Kaboo R, Tso CL, Moldawer N, Gitlitz B, DeKernion J, Belldegrun A (1997) Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 158:740-745 10.1097/ 00005392-199709000-00012
34. Fairlamb DJ (1981) Spontaneous regression of metastases of RCC: A report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer 47:2102-2106
35. Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belldegrun AS (1999) Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17:2521-2529
36. Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG (2003) Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 21:884-890
37. Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, Seki N, Wigginton JM, Wilson SE, Blazar BR, Malyguine AM, Sayers TJ, Wiltrout RH (2003) Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: Coordination of dendritic and CD8+ cell responses. J Immunol 170:2727-2733
38. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: Feasibility, engraftment, and clinical results. J Clin Oncol 20:2017-2024
39. Blaise D, Bay JO, Faucher C et al. (2004) Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 103:435-441 10.1182/blood-2003-07-2236
40. Massenkeil G, Roigas J, Nagy M, Wille A, Stroszczynski C, Mapara MY, Loening S, Dörken B, Arnold R (2004) Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: Delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant 34:309-316 10.1038/sj.bmt.1704587
41. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I, Voena C, Zaniboni A, Bordignon C, Corradini P (2002) Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99:4234-4236 10.1182/blood.V99.11.4234
42. Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, Landonio G, Locatelli F, Siena S, Della Cuna GR (2002) Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: A pilot study in patients with refractory malignancies. Cancer 94:2409-2415
43. Hentschke P, Barkholt L, Uzunel M, Mattsson J, Wersall P, Pisa P, Martola J, Albiin N, Wernerson A, Soderberg M, Remberger M, Thorne A, Ringden O (2003) Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 31:253-261 10.1038/sj.bmt.1703811
44. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE (2003) Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102:3829-3836 10.1182/ blood-2003-04-1022
45. Nakagawa T, Kami M, Hori A, Kim SW, Murashige N, Hamaki T, Kishi Y, Fujimoto H, Matsuoka N, Okajima E, Komiyama M, Tobisu K, Wakayama T, Uike N, Tajima K, Makimoto A, Mori S, Tanosaki R, Takaue Y, Kakizoe T (2004) Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: Single institution experience with a minimum 1-year follow-up. Exp Hematol 32:599-606 10.1016/j.exphem.2004.04.006
46. Massenkeil G, Nagy M, Heine F, Le Coutre P, Neuburger S, Rosen O, Wernecke KD, Dörken B, Arnold R (2004) Survival after nonmyeloablative stem cell transplantation is comparable to conventional stem cell transplantation in acute leukemias. Onkologie 27 [Suppl 3]: abstract 290
47. Mohty M, Faucher C, Vey N, Stoppa AM, Viret F, Chabbert I, Chabannon C, Bouabdallah R, Ladaique P, Collet L, Zandotti C, Maraninchi D, Blaise D (2000) High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 26:251-255 10.1038/sj.bmt.1702509
48. International Bone Marrow Transplant Registry (IBMTR) Database (2003) Current use and outcome of blood and marrow transplantation 2003. www.ibmtr.org
49. Kernan NA (1999) T-cell depletion for the prevention of graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ (eds), Hematopoietic cell transplantation, 2nd edn. Blackwell Science, Malden, pp 186-196
50. Baron F, Frere P, Baudoux E, Schaaf-Lafontaine N, Fillet G, Beguin Y (2003) Low incidence of acute graft-versus-host disease after non-myeloablative stem cell transplantation with CD8-depleted peripheral blood stem cells: An update. Haematologica 88:835-837
51. Sauer MG, Ericson ME, Weigel BJ, Herron MJ, Panoskaltsis-Mortari A, Kren BT, Levine BL, Serody JS, June CH, Taylor PA, Blazar BR (2004) A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. Cancer Res 64:3914-3921